Highly exuding wounds are common and can result in malodour, pain, maceration, infection and unsightly soiled dressings, as well as having a negative impact on an individual's quality of life. This communication reports on the findings from an evaluation by nurses regarding the clinical effectiveness and safety of superabsorbent dressing KerraMax Care and the patient experience of KerraMax Care in the management of moderate to highly exuding wounds. A total of 54 evaluations were completed. Nurses commented on the main benefits seen clinically with KerraMax Care as being reduced maceration, exudate managed and improved wound appearance. Other changes observed in wound appearance noted were visible granulation tissue and reduced pain. The evaluation demonstrates the positive impact that good dressing selection can have on the lives of patients, improving their wound-care experience and outcome.
Superabsorbent dressings
Increasing the frequency of dressing changes should no longer be the first coping strategy initiated by clinicians to manage exudate. Indeed, this may not be the option of choice for the patient either. Not only does this add to the cost (as nursing time is the most expensive aspect of wound management), but dressing change is often a traumatic and painful time for patients (Meaume et al, 2004; Woo, 2010) . A thorough assessment followed by careful dressing selection should therefore be the starting point. Butcher and White (2013) remind us not to neglect, or even disregard, the views and concordance of the patient in any decision-making process.
Four dressings are classified in the British National Formulary (BNF) (Joint Formulary Committee, 2013) as absorbent dressings for heavily exuding wounds. They are made of superabsorbent polymers (SAPs) with a greater absorption capacity than traditional foam dressings and the ability to bind or retain fluid by converting it into a gel, locking it away within the dressing. Jones and Barraud (2013) report the results of an evaluation by 21 experienced and specialist clinicians on their requirements and expectations for superabsorbent dressings in the management of exuding wounds of various aetiologies. It was postulated that dressing changes are not predominantly determined by dressings reaching capacity. Indeed, there may be a ceiling effect of 100 mLs with absorption beyond that capacity conferring no additional benefit.
A greater consideration than absorption capacity is the ability of the dressing to retain wound fluid, especially under pressure.
Superabsorbents have the ability to trap unwanted components of the exudate, such as bacteria, proteases and inflammatory mediators, within the core of the dressing (Wiegand et al, 2011) , reducing matrix metalloproteinase (MMP) levels (Eming et al, 2008) ; and they are designed to reduce potential leaks and risk of maceration. This translates to the ability to reduce dressing change frequency. White and Cutting (2006) note that the challenge in managing heavily exuding wounds is to maintain a moist wound-dressing interface, while effectively absorbing and retaining excess exudate. The product needs to lock the exudate into the dressing in order to protect the wound bed and surrounding skin, to perform under compression, to be easy to remove and to be cost-effective. However, focusing on unit cost as the sole criterion for dressing choice is misguided. Using products correctly involves knowing what the product is able to do, e.g. whether it absorbs and retains the fluid. Cutting and White (2012) remind clinicians of their responsibility in identifying and selecting clinical interventions that achieve optimal patient outcomes in a given clinical circumstance. Superabsorbent dressings give good protection to the periwound skin from the corrosive and painful effect of the exudate (Langoen and Lawton, 2009 (0: increased maceration. 10: reduced maceration)
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Evaluation of KerraMax Care
KerraMax Care is a new version of KerraMax superabsorbent dressing.
KerraMax Care has an improved contact layer, together with a horizontal wicking layer to ensure even distribution of exudate. It also has heatsealed borders to prevent leakage. KerraMax Care can be used as a primary or secondary absorbent layer, for example, over a cavity or where an antimicrobial is used as the primary dressing (Hampton et al, 2011 ).
The primary objective of the evaluation was to understand the experiences of clinicians regarding the clinical effectiveness and safety of KerraMax Care and the patient experience of KerraMax Care in the management of moderate to highly exuding wounds.
Method
Clinicians who had previously used KerraMax were asked to complete The majority of exuding wounds treated during the evaluation period were due to ulceration; however, 26 evaluations did not state the aetiology of the wound (Figure 1) . The clinicians were asked to show whether the exudate was serous (defined as thin and straw coloured) or purulent (defined as yellow and thicker). In 25 of the wounds treated, the exudate was classed as serous, while in 17 cases it was defined as purulent. It was noted that all the wounds treated in this evaluation were moderate to heavily exuding wounds.
Clinicians were asked how they rated KerraMax Care in terms of managing the exudate from the ulcer (from 0 to 10, with 0 reflecting poor exudate management and 10 good management), compared with previous dressing choices. There were 43 nurses who scored the KerraMax Care between 7 and 10 for exudate management with a mean score of 7.5 and a median score of 8 (Figure 2 In 26 out of 54 cases surveyed, the aetiology was not given. Clinicians recorded that maceration of surrounding skin tended to be reduced.
mould around legs. Only 2 respondents would not be happy to continue using KerraMax Care but were unable to provide a reason, while 1 respondent remained undecided. 
Discussion
CWC
